Calcium and osteoprotegerin regulate IGF1R expression to inhibit vascular calcification

Cardiovascular Research

Volumn 91, Issue 3, 2011, Pages 537-545

  Di Bartolo, Belinda A ^a   Schoppet, Michael ^b   Mattar, Muhammad Z ^a   Rachner, Tilman D ^b   Shanahan, Catherine M ^c   Kavurma, Mary M ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Calcium; IGF1R; Osteoprotegerin; Smooth muscle cell; Vascular calcification

Indexed keywords

CALCIUM; CAMPTOTHECIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; OSTEOPROTEGERIN; PROTEIN BCL 2; SMALL INTERFERING RNA; SOMATOMEDIN C; TRANSCRIPTION FACTOR SP1;

APOPTOSIS; ARTICLE; BLOOD VESSEL CALCIFICATION; HUMAN; HUMAN CELL; MINERALIZATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; UPREGULATION;

ANIMALS; APOPTOSIS; CALCINOSIS; CALCIUM; CAMPTOTHECIN; CELLS, CULTURED; FEEDBACK, PHYSIOLOGICAL; GENE EXPRESSION REGULATION; HUMANS; MUSCLE, SMOOTH, VASCULAR; MUTATION; MYOCYTES, SMOOTH MUSCLE; NF-KAPPA B; OSTEOPROTEGERIN; PROTO-ONCOGENE PROTEINS C-BCL-2; RATS; RECEPTOR, IGF TYPE 1; RNA INTERFERENCE; RNA, MESSENGER; SP1 TRANSCRIPTION FACTOR; TIME FACTORS; TRANSFECTION; VASCULAR DISEASES;

EID: 79959887174     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvr084     Document Type: Article

References (46)

1. LeGeros RZ. Formation and transformation of calcium phosphates: relevance to vascular calcification. Z Kardiol 2001;90:116-124. (Pubitemid 32291176)
2. Duer MJ, Friscic T, Proudfoot D, Reid DG, Schoppet M, Shanahan CM et al. Mineral surface in calcified plaque is like that of bone: further evidence for regulated mineralization. Arterioscler Thromb Vasc Biol 2008;28:2030-2034.
3. Collin-Osdoby P. Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin. Circ Res 2004;95:1046-1057. (Pubitemid 39557891)
4. Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998;12:1260-1268. (Pubitemid 28213402)
5. Schoppet M, Shroff RC, Hofbauer LC, Shanahan CM. Exploring the biology of vascular calcification in chronic kidney disease: what's circulating? Kidney Int 2008;73:384-390. (Pubitemid 351186286)
6. Hamano K, Li TS, Kobayashi T, Kobayashi S, Matsuzaki M, Esato K. Angiogenesis induced by the implantation of self-bone marrow cells: a new material for therapeutic angiogenesis. Cell Transplant 2000;9:439-443. (Pubitemid 30655695)
7. Morony S, Tintut Y, Zhang Z, Cattley RC, Van G, Dwyer D et al. Osteoprotegerin inhibits vascular calcification without affecting atherosclerosis in ldlr(2/2) mice. Circulation 2008;117:411-420.
8. Lawrie A, Waterman E, Southwood M, Evans D, Suntharalingam J, Francis S et al. Evidence of a role for osteoprotegerin in the pathogenesis of pulmonary arterial hypertension. Am J Pathol 2008;172:256-264.
9. Bennett BJ, Scatena M, Kirk EA, Rattazzi M, Varon RM, Averill M et al. Osteoprotegerin inactivation accelerates advanced atherosclerotic lesion progression and calcification in older ApoE2/2 mice. Arterioscler Thromb Vasc Biol 2006;26:2117-2124. (Pubitemid 44253797)
10. Kavurma MM, Figg N, Bennett MR, Mercer J, Khachigian LM, Littlewood TD. Oxidative stress regulates IGF1R expression in vascular smooth muscle cells via p53 and HDAC recruitment. Biochem J 2007;407:79-87. (Pubitemid 47535583)
11. Valentinis B, Baserga R. IGF-I receptor signalling in transformation and differentiation. Mol Pathol 2001;54:133-137. (Pubitemid 32539602)
12. Delafontaine P, Song YH, Li Y. Expression, regulation, and function of IGF-1, IGF-1R, and IGF-1 binding proteins in blood vessels. Arterioscler Thromb Vasc Biol 2004;24: 435-444. (Pubitemid 38326135)
13. Kavurma MM, Bennett MR. Expression, regulation and function of trail in atherosclerosis. Biochem Pharmacol 2008;75:1441-1450. (Pubitemid 351375180)
14. Kasukawa Y, Baylink DJ, Wergedal JE, Amaar Y, Srivastava AK, Guo R et al. Lack of insulin-like growth factor I exaggerates the effect of calcium deficiency on bone accretion in mice. Endocrinology 2003;144:4682-4689. (Pubitemid 37378375)
15. Radcliff K, Tang TB, Lim J, Zhang Z, Abedin M, Demer LL et al. Insulin-like growth factor-I regulates proliferation and osteoblastic differentiation of calcifying vascular cells via extracellular signal-regulated protein kinase and phosphatidylinositol 3-kinase pathways. Circ Res 2005;96:398-400. (Pubitemid 40354532)
16. Gordon D, Mohai LG, Schwartz SM. Induction of polyploidy in cultures of neonatal rat aortic smooth muscle cells. Circ Res 1986;59:633-644. (Pubitemid 17035308)
17. Gregory CA, Gunn WG, Peister A, Prockop DJ. An Alizarin red-based assay of ineralization by adherent cells in culture: comparison with cetylpyridinium chloride extraction. Anal biochem 2004;329:77-84. (Pubitemid 38596903)
18. Kavurma MM, Santiago FS, Bonfoco E, Khachigian LM. Sp1 phosphorylation regulates apoptosis via extracellular FasL-Fas engagement. J Biol Chem 2001;276:4964-4971.
19. Reynolds JL, Joannides AJ, Skepper JN, McNair R, Schurgers LJ, Proudfoot D et al. Human vascular smooth muscle cells undergo vesicle-mediated calcification in response to changes in extracellular calcium and phosphate concentrations: a potential mechanism for accelerated vascular calcification in ESRD. J Am Soc Nephrol 2004; 15:2857-2867. (Pubitemid 41103395)
20. Werner H, Karnieli E, Rauscher FJ, LeRoith D. Wild-type and mutant p53 differentially regulate transcription of the insulin-like growth factor I receptor gene. Proc Natl Acad Sci USA 1996;93:8318-8323. (Pubitemid 26269555)
21. Vincent AM, Feldman EL. Control of cell survival by IGF signaling pathways. Growth Horm IGF Res 2002;12:193-197. (Pubitemid 35230190)
22. Takami M, Takahashi N, Udagawa N, Miyaura C, Suda K, Woo JT et al. Intracellular calcium and protein kinase C mediate expression of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in osteoblasts. Endocrinology 2000;141: 4711-4719. (Pubitemid 32055151)
23. Beitner-Johnson D, Werner H, Roberts CT Jr, LeRoith D. Regulation of insulin-like growth factor I receptor gene expression by Sp1: physical and functional interactions of Sp1 at GC boxes and at a CT element. Mol Endocrinol 1995;9: 1147-1156.
24. Petersohn D, Thiel G. Role of zinc-finger proteins Sp1 and zif268/egr-1 in transcriptional regulation of the human synaptobrevin II gene. Eur J Biochem 1996;239:827-834. (Pubitemid 26253060)
25. Kavurma MM, Tan NY, Bennett MR. Death receptors and their ligands in atherosclerosis. Arterioscler Thromb Vasc Biol 2008;28:1694-1702.
26. Wallin R,Wajih N, Greenwood GT, Sane DC. Arterial calcification: a review of mechanisms, animal models, and the prospects for therapy. Med Res Rev 2001;21:274-301. (Pubitemid 32565495)
27. Jorde R, Sundsfjord J, Fitzgerald P, Bonaa KH. Serum calcium and cardiovascular risk factors and diseases: the Tromso study. Hypertension 1999;34:484-490. (Pubitemid 29426768)
28. Reddy J, Bilezikian JP, Smith SJ, Mosca L. Reduced bone mineral density is associated with breast arterial calcification. J Clin Endocrinol Metab 2008;93:208-211.
29. Hofbauer LC, Schoppet M. Clinical implications of the osteoprotegerin/RANKL/ RANK system for bone and vascular diseases. JAMA 2004;292:490-495. (Pubitemid 38988958)
30. Kiechl S, Schett G, Wenning G, Redlich K, Oberhollenzer M, Mayr A et al. Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation 2004;109:2175-2180. (Pubitemid 38625393)
31. Schoppet M, Sattler AM, Schaefer JR, Herzum M, Maisch B, Hofbauer LC. Increased osteoprotegerin serum levels in men with coronary artery disease. J Clin Endocrinol Metab 2003;88:1024-1028. (Pubitemid 36337751)
32. Shroff RC, McNair R, Skepper JN, Figg N, Schurgers LJ, Deanfield J et al. Chronic mineral dysregulation promotes vascular smooth muscle cell adaptation and extracellular matrix calcification. J Am Soc Nephrol 2010;21:103-112.
33. Schoppet M, Al-Fakhri N, Franke FE, Katz N, Barth PJ, Maisch B et al. Localization of osteoprotegerin, tumor necrosis factor-related apoptosis-inducing ligand, and receptor activator of nuclear factor-kappaB ligand in Monckeberg's sclerosis and atherosclerosis. J Clin Endocrinol Metab 2004;89:4104-4112. (Pubitemid 39071519)
34. Nitta K, Akiba T, Uchida K, Otsubo S, Takei T, Yumura W et al. Serum osteoprotegerin levels and the extent of vascular calcification in haemodialysis patients. Nephrol Dial Transplant 2004;19:1886-1889. (Pubitemid 38961404)
35. Browner WS, Lui LY, Cummings SR. Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J Clin Endocrinol Metab 2001;86:631-637. (Pubitemid 32207471)
36. Kazama JJ, Shigematsu T, Yano K, Tsuda E, Miura M, Iwasaki Y et al. Increased circulating levels of osteoclastogenesis inhibitory factor (osteoprotegerin) in patients with chronic renal failure. Am J Kidney Dis 2002;39:525-532. (Pubitemid 34194628)
37. Dhore CR, Cleutjens JP, Lutgens E, Cleutjens KB, Geusens PP, Kitslaar PJ et al. Differential expression of bone matrix regulatory proteins in human atherosclerotic plaques. Arterioscler Thromb Vasc Biol 2001;21:1998-2003. (Pubitemid 34219753)
38. Panizo S, Cardus A, Encinas M, Parisi E, Valcheva P, Lopez-Ongil S et al. RANKL increases vascular smooth muscle cell calcification through a RANK-BMP4-dependent pathway. Circ Res 2009;104:1041-1048.
39. Helas S, Goettsch C, Schoppet M, Zeitz U, Hempel U, Morawietz H et al. Inhibition of receptor activator of NF-kappaB ligand by denosumab attenuates vascular calcium deposition in mice. Am J Pathol 2009;175:473-478.
40. Proudfoot D, Skepper JN, Hegyi L, Bennett MR, Shanahan CM, Weissberg PL. Apoptosis regulates human vascular calcification in vitro: evidence for initiation of vascular calcification by apoptotic bodies. Circ Res 2000;87:1055-1062.
41. Patel VA, Zhang QJ, Siddle K, Soos MA, Goddard M, Weissberg PL et al. Defect in insulin-like growth factor-1 survival mechanism in atherosclerotic plaque-derived vascular smooth muscle cells is mediated by reduced surface binding and signaling. Circ Res 2001;88:895-902. (Pubitemid 32441467)
42. Kavurma MM, Schoppet M, Bobryshev YV, Khachigian LM, Bennett MR. Trail stimulates proliferation of vascular smooth muscle cells via activation of NF-kappa B and induction of insulin-like growth factor-1 receptor. J Biol Chem 2008;283:7754-7762.
43. Reid P, Holen I. Pathophysiological roles of osteoprotegerin (OPG). Eur J Cell Biol 2009;88:1-17.
44. Liacini A, Sylvester J, Li WQ, Zafarullah M. Mithramycin downregulates proinflammatory cytokine-induced matrix metalloproteinase gene expression in articular chondrocytes. Arthritis Res Ther 2005;7:R777-R783.
45. Xu J, Rogers MB. Modulation of bone morphogenetic protein (BMP) 2 gene expression by Sp1 transcription factors. Gene 2007;392:221-229. (Pubitemid 46486691)
46. Mann V, Hobson EE, Li B, Stewart TL, Grant SF, Robins SP et al. A COL1A1 Sp1 binding site polymorphism predisposes to osteoporotic fracture by affecting bone density and quality. J Clin Invest 2001;107:899-907. (Pubitemid 32274043)